Sphera Funds Management’s Cogent Biosciences COGT Stock Holding History

Sphera Funds Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.8M	Buy	459,340 +43,000	+10%	+$1.5M	2.32%	12
2026 Q1	$16M	Buy	416,340 +37,840	+10%	+$1.4M	2.54%	11
2025 Q4	$13.4M	Buy	378,500 +279,974	+284%	+$7.87M	2.6%	7
2025 Q3	$1.41M	Sell	98,526 -45,167	-31%	-$535K	0.3%	84
2025 Q2	$1.03M	Sell	143,693 -191,331	-57%	-$1.06M	0.24%	87
2025 Q1	$2.01M	Buy	+335,024	New	+$2.63M	0.46%	67
2024 Q1	–	Sell	-259,201	Closed	-$1.52M	–	109
2023 Q4	$1.52M	Sell	259,201 -160,799	-38%	-$1.23M	0.25%	79
2023 Q3	$4.09M	Hold	420,000	–	–	0.75%	48
2023 Q2	$4.97M	Buy	420,000 +120,000	+40%	+$1.38M	0.78%	51
2023 Q1	$3.24M	Buy	+300,000	New	+$3.84M	0.54%	55
2021 Q2	–	Sell	-762,569	Closed	-$6.7M	–	144
2021 Q1	$6.7M	Buy	762,569 +27,135	+4%	+$261K	0.51%	60
2020 Q4	$8.26M	Buy	+735,434	New	+$8.08M	0.73%	43

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sphera Funds Management's COGT Position: Q2 2026 in Review

Sphera Funds Management increased its Cogent Biosciences (COGT) stake by 10% in Q2 2026, buying an estimated $1.5M and bringing the position to 459,340 shares worth $17.8M. The position accounts for 2.32% of the portfolio, ranked #12.

Sphera Funds Management first reported a position in COGT in Q4 2020 and has held it in 12 quarters since. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Sphera Funds Management held 459,340 shares of Cogent Biosciences worth $17.8M as of Q2 2026.
Sphera Funds Management bought 43,000 Cogent Biosciences shares in Q2 2026, an estimated $1.5M.
Cogent Biosciences made up 2.32% of Sphera Funds Management's portfolio in Q2 2026, its #12 holding.
Sphera Funds Management first reported a position in Cogent Biosciences in Q4 2020 and has held it in 12 quarters since.
322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.